Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

NBIX POWR Grades

• NBIX scores best on the Quality dimension, with a Quality rank ahead of 97.17% of US stocks.
• The strongest trend for NBIX is in Stability, which has been heading down over the past 26 weeks.
• NBIX's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).

NBIX Stock Summary

• NBIX's current price/earnings ratio is 68.28, which is higher than 90.46% of US stocks with positive earnings.
• Price to trailing twelve month operating cash flow for NBIX is currently 31.85, higher than 87.42% of US stocks with positive operating cash flow.
• Over the past twelve months, NBIX has reported earnings growth of 170.46%, putting it ahead of 93.2% of US stocks in our set.
• Stocks that are quantitatively similar to NBIX, based on their financial statements, market capitalization, and price volatility, are DV, ITRI, NOVT, THRM, and ONTO.
• Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.

NBIX Valuation Summary

• In comparison to the median Healthcare stock, NBIX's EV/EBIT ratio is 244.52% higher, now standing at 50.3.
• NBIX's price/earnings ratio has moved up 93.8 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

NBIX Growth Metrics

Its 3 year price growth rate is now at 15.15%.
• The year over year net cashflow from operations growth rate now stands at -53.64%.
• Its 3 year net cashflow from operations growth rate is now at 370.41%.

Over the past 52 months, NBIX's revenue has gone up $1,074,435,000.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	1,488.7	339.4	154.5
2022-09-30	1,388.7	200.6	58.2
2022-06-30	1,296.8	163.6	12.2
2022-03-31	1,207.5	128.7	71.4
2021-12-31	1,133.5	256.5	89.6
2021-09-30	1,069.4	341.2	444.8

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
• NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
• LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.